Combio - Terveydenhuollon biomateriaalit

Tekes – Focusing on Biomaterial Technology

Ms. Aila Maijanen

Tekes,

National Technology Agency of Finland

Senior Technology Advisor

Tekes

Focusing on biomaterial technology

Human Spare PartsOct 21, 2004 - Brussels

Aila MaijanenNational Technology Agency Tekes

Senior technology advisor

Content:

National Technology Agency Tekes: Mission and Activities

Tekes Technology Programmes

Combio – Commercialisation of BiomaterialsTechnology Programme

Conclusion

Public sector activities of R&D in Finland

Ministry ofTrade andIndustry

DM 32190 04-2003 Copyright © Tekes

Academyof

Finland

Universities

Ministry ofTrade andIndustry

SitraFinnvera Oyj

Finpro

PARLIAMENT

GOVERNMENT

VTT

Tekes

Science andTechnology

PolicyCouncil

RegionalTE-Centres

Otherministriesand theirinstitutes

Ministryof

Education

Tekes’ mission statement

Tekes’ primary objective is to promote thecompetitiveness of Finnish industry and

the service sector by technological means.

Activities aim to diversify production structures,increase production and exports, and create a

foundation for employment and societal well-being.

DM 3218904-2003 Copyright © Tekes

Tekes core activities

Selective project funding

Technology programmes


Development of the innovationenvironment

Activation for innovation

Regionaltechnologicalcooperation

and promotionof regional

success

Internationaltechnologicalcooperation

andinternationalexpansion ofcompanies

0

50

100

150

200

250

300

350

400

450

500

1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

349

386

316

252 244

386 395415

390 379

Tekes technology funding in the state budget

Million euros


National share of EU Structural FundsIndustrial R&D loansCapital loans for R&DIndustrial R&D grantsCoordination of programmesResearch funding

During the years 2000-2004 Tekes also had an annual allocation of 5-10 million euros from the EU Structural Funds as the EU share.

The funding resources for industrial R&D loans and capital loans for R&D merged in 2004.

Tekes Overseas Offices


Helsinki

Brussels

San JoseWashington, D.C.

Tokyo

Beijing

Technology Units at the TE-Centres


Technology units at the Employment and Economic Development Centres (TE-Centres) offer Tekes' services to companies and research units.

Technology units at the Employment and Economic Development Centres (TE-Centres) offer Tekes' services to companies and research units.

Lapland

Oulu

Kajaani

SeinäjokiKuopio

JyväskyläJoensuu

MikkeliTampere

PoriLappeenranta

Turku Tekes, Helsinki

Vaasa

Lahti

Information andcommunications technology

115 million euros

Other funding4 million euros

Total Tekes R&D funding in 2003by field of technology

Space activities18 million euros

Bio- and chemicaltechnology107 million euros

Product andproduction technology74 million euros

Energy, environment andconstruction technologies

74 million euros


Total 392 million euros and2,196 projects

Total 392 million euros and2,196 projects

Total funding 162 million euros and801 projects

Total funding 162 million euros and801 projects

VTT 36 million euros

Participation feesfor ESA programmes, 13 million euros

Other research funding8 million euros

Universities102 million euros

Tekes research fundingin 2003

Other research institutes3 million euros

In many research projects there are participantsfrom several universities or research institutes.


Technology programme model

Steering groupenterprises

TekesGrants

Company R&D projects

Research projects of research institutes and universities

SynergyNetworking

Part financing

preparationcoordinationdecision

making


GrantsLoans

Capital loans

Pictures: © ESA, Okmetic, Stora Enso

Picture: © Elcotec

Bio- and Chemical Technology


Technology programmes in 2004

2000-2004

2001-2004

2001-2004

2001-2006

2003-2006

2003-2007

20

42

87

110

21

26

18

33

10

11

2

23

27

56

50

34

5

18

Process Integration *

Innovation in Foods

NeoBio - Novel Biotechnology *

Drug 2000 **

Wood Material Science

COMBIO - Commercialisation of Biomaterials

= Intertechnological programme = In cooperation with the Academy of Finland

***

Totalbudget

mill. euros

Participatingresearch

unitscompa-

nies


COMBIO - Commercialisation of Biomaterials

The goal of the COMBIO programme is to further develop the strong Finnish biomaterial technology

base in health care and to use business technologies to support the commercialisation of research results

The goal of the COMBIO programme is to further develop the strong Finnish biomaterial technology

base in health care and to use business technologies to support the commercialisation of research results

Time span: 2003-2007Extent: Approximately 26 million eurosResponsibility: Mika Sievi-Korte, Tekes

Aila Maijanen, TekesProgramme Manager: Heikki Laurila,

Frux Advisors Ltd.Further information: www.tekes.fi/ohjelmat/combio

How to enhance commercialisation of medical biomaterials research ?

focusing on market-driven opportunitiestraining of business skills, IPR and regulatory

issues long-term funding of research and R&D in key

technologiesincreasing the critical mass of research projectspromoting collaboration within Finlandpromoting the biomaterials field for vc’spromoting the internationalisation of Finnish

biomaterials companies

Background

The ageing population is the single most important reason for the rapid growth of the biomaterials sector in health care

The number of persons over 60 years is growing at a rate of 1.5 percent annually

the human body is “designed” to hold out for 30-40 years many tissues start to deteriorate at an increasing speed

after the age of 30 tissues can be repaired using biomaterials and by

combining tissue engineering and stem cell technology with biomaterials

Other sources of growth are new technologies in administering drugs and the evolutionary development of several surgical products that are implementing the use of biomaterials


Structure and Development

Globally, there are about 7,500 companies in the sectorTurnover is about 50 billion euros

an average of 6.5 million euros/company

The growth of different market segments varies between 8 and 40 percent annually

the average market growth of the pharmaceutical industry is 8 percent annually

Growth in the first half of 2003 was even more rapid than expected

there have been extensive mergers and acquisitions in 2003 because companies are seeking new technologies and distribution channels (M&A has not done away with overcapacity)


3-5 globally-acting companies in Finland in 2010Turnover 500 million euros (or even more)

the turnover from subcontractors has to be added to the above

80 percent of existing companies will disappear due to mergers and closures

even in the case of a closure, know-how will remain in Finland and is transferable to other companies

New companies with similar courses of development will constantly appear (80 percent will disappear)


Vision

Focus Areas

Materials and methods in tissue engineeringNew materials for drug delivery Implants

MAIN FOCUS: COMMERCIALISATION!

The programme focuses on three technology areasThe programme focuses on three technology areas


Material technologyBiomechanical modelling

Cell biologyStem cell research

Programme structure:

New materialsfor drug delivery

Multifunctionalimplants

Tissue engineering:bone

soft tissuecartilage

Company R&D Projects Company R&D Projects

Company R&D projects Company R&D projects

Themes for Public Projects

1. Biological materials and composites for artificial tissues

2. Bone tissue engineering from stem cells and scaffolds

3. Implants for tissue engineering

4. Release of drugs, structural studies and modelling 5. Biomaterials in ophthalmic surgery

6. Photopolymerisable gels

7. Implants based on memory metals

8. Multifunctional biomaterials

9. Biomechanically optimised multicomponent implants

10. Antimicrobial properties of bioactive glass and Si gel

11. Porous biodegradable or bioactive material

12. Optical fibre composite for medicine and dentistry

13. Bioactive resorbable composite for bone repair


State of the Programme

Participating research units 23

Participating companies 24

Projects underway 20 research projects 13 company projects 7


Conclusion:

Finland provides an excellent infrastructure for research and R&D on biomaterials and tissue engineering due to advanced

educational system public health care innovation and technology policy

proven process including basic reseach preclinical and clinical research product development process development full-scale manufacturing

Products taken from lab to market!

Thank You!

Combio - Terveydenhuollon biomateriaalit

Documents

Transcript of Combio - Terveydenhuollon biomateriaalit